The Discounted Cash Flow (DCF) valuation of Basilea Pharmaceutica AG (BSLN.SW) is 74.53 CHF. With the latest stock price at 55.10 CHF, the upside of Basilea Pharmaceutica AG based on DCF is 35.3%.
Based on the latest price of 55.10 CHF and our DCF valuation, Basilea Pharmaceutica AG (BSLN.SW) is a buy. buying BSLN.SW stocks now will result in a potential gain of 35.3%.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 7.6% | 6.3% |
| Long-term Growth Rate | 0.5% - 1.5% | 1.0% |
| Fair Price | 58.29 - 107.22 | 74.53 |
| Upside | 5.8% - 94.6% | 35.3% |